Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pilocarpine hydrochloride
Drug ID BADD_D01771
Description A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.
Indications and Usage For the treatment of radiation-induced dry mouth (xerostomia) and symptoms of dry mouth in patients with Sjögrens syndrome.
Marketing Status Discontinued; Prescription
ATC Code N07AX01; S01EB01
DrugBank ID DB01085
KEGG ID D02200
MeSH ID D010862
PubChem ID 5909
TTD Drug ID D06HLY
NDC Product Code 63629-2099; 17478-224; 0115-5911; 0074-7098; 0998-0204; 69205-001; 69238-1745; 69238-1746; 59212-775; 50384-0400; 59651-225; 38779-0182; 61314-204; 0527-1313; 17478-223; 51927-1528; 0228-2837; 0115-5922; 0998-0206; 16714-122; 61314-203; 50268-652; 0998-0203; 16714-121; 0228-2801; 63279-100; 17478-226; 0527-1407; 59651-224; 63629-8351; 12538-1921; 61314-206; 69238-1747; 68084-928; 59212-705
Synonyms Pilocarpine | Isoptocarpine | Salagen | Pilocarpine Hydrochloride | Hydrochloride, Pilocarpine | Pilocarpine, Monohydrochloride, (3S-cis)-Isomer | Pilocarpine Nitrate | Nitrate, Pilocarpine | Pilocarpine Mononitrate, (3S-cis)-Isomer | Isopilocarpine | Ocusert
Chemical Information
Molecular Formula C11H17ClN2O2
CAS Registry Number 54-71-7
SMILES CCC1C(COC1=O)CC2=CN=CN2C.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Seizures (incl subtypes)Delta-type opioid receptorP41143T58992Not Available
Seizures (incl subtypes)Mu-type opioid receptorP35372T47768Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethral pain20.02.02.014--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urine analysis13.13.02.022--Not Available
Vaginal haemorrhage24.07.03.005; 21.08.01.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Viral infection11.05.04.001--Not Available
Vision blurred06.02.06.007; 17.17.01.010--
Visual acuity reduced06.02.03.001; 17.17.01.011--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
White blood cell count abnormal13.01.06.028--Not Available
Yawning22.02.05.017--Not Available
Macular hole06.09.03.009--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.001--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
White blood cell disorder01.02.05.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Lacrimal disorder06.08.02.005--Not Available
Blood disorder01.05.01.004--Not Available
Increased bronchial secretion22.02.04.007--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Lacrimal structural disorder06.06.04.013--Not Available
Candida infection11.03.03.021--
The 7th Page    First    Pre   7    Total 7 Pages